Using data from recent clinical trials, the 2019 Update of the CCS/CHSF HF Guidelines provides recommendations and practical tips regarding:
- transcatheter mitral valve repair in HFrEF,
- novel treatments for ATTR or transthyretin cardiac amyloidosis,
- ARNI in patients with HFpEF, and
- SGLT2 inhibitors for the prevention and treatment of HF in patients with or without type 2 diabetes.
New report shows access to and wait times for life-saving cardiac procedure depends on where you live, highlights need for new approaches to ensure pan-Canadian equity
In the last decade, transcatheter aortic valve implantation (TAVI) – an innovative, non-invasive surgical procedure – has become the preferred treatment option for many heart patients. Yet the latest pan-Canadian data on TAVI care shows that access is highly variable across Canada and that healthcare resources are not keeping pace with the growing healthcare need.
The Canadian Cardiovascular Society announces recipients of the Early Career Atrial Fibrillation and Arrhythmia Award.
The Canadian Cardiovascular Society (CCS) is pleased to recognize seven outstanding Canadian researchers whose five projects have been selected to receive funding as part of the Early Career Atrial and Arrythmia (ECA3) Research Award.
The Canadian Cardiovascular Society (CCS) has announced the three finalists in the CCS-Bayer Vascular Awards competition.
Despite best efforts and major support at the highest level of government, federal Budget 2019 shows no sign of funds for the CCS Quality Project. Without this year’s federal funding commitment, the CCS will have no choice but to scale down the project, limiting our ability to advance quality cardiovascular care in Canada.